| Is It Time To Buy AbbVie Stock At $180? |
AbbVie (NYSE:ABBV) stock has garnered recent attention following the FDA approval of Emrelis for adults with previously treated lung cancer who exhibit an overabundance of the c-Met protein. This protein is known to promote tumor growth and resistance to certain therapies. |
forbes.com |
2025-05-16 12:30:04 |
Czytaj oryginał (ang.) |
| June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV |
NEW YORK , May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. |
prnewswire.com |
2025-05-16 09:45:00 |
Czytaj oryginał (ang.) |
| The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ABBV |
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). |
globenewswire.com |
2025-05-15 18:01:00 |
Czytaj oryginał (ang.) |
| AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer |
Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression. |
zacks.com |
2025-05-15 13:46:06 |
Czytaj oryginał (ang.) |
| The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV |
NEW YORK , May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
prnewswire.com |
2025-05-15 09:45:00 |
Czytaj oryginał (ang.) |
| Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer |
Ongoing tariff disputes and President Trump's drug pricing order heighten uncertainties for AbbVie Inc. and Pfizer Inc. The more uncertain the time, the more investors should focus on return vectors that are less ambiguous. ABBV's superior dividend track record, safer payout ratio, consistent share buybacks, and robust margins make it an overall better package compared to PFE. |
seekingalpha.com |
2025-05-14 20:36:16 |
Czytaj oryginał (ang.) |
| AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript) |
AbbVie Inc. (NYSE:ABBV ) BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ET Company Participants Jeff Stewart - EVP and Chief Commercialization Officer Roopal Thakkar - EVP and R&D, Chief Scientific Officer Scott Reents - EVP and CFO Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us for this next session. I'm Tim Anderson, the U.S. large-cap pharma and biotech analyst at Bank of America. |
seekingalpha.com |
2025-05-14 19:10:41 |
Czytaj oryginał (ang.) |
| Calls of the Day: RobinHood, UnitedHealth, Abbvie and Lowe's |
The Investment Committee debate the latest Calls of the Day. |
youtube.com |
2025-05-14 17:35:37 |
Czytaj oryginał (ang.) |
| Lost Money on Cerevel Therapeutics Holdings, Inc. (ABBV)? Contact Levi & Korsinsky Before June 3, 2025 to Join Class Action |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=148519&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-14 17:30:00 |
Czytaj oryginał (ang.) |
| US FDA approves AbbVie's drug for a type of lung cancer |
The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday. |
reuters.com |
2025-05-14 17:23:26 |
Czytaj oryginał (ang.) |
| U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression |
– EMRELIS is the first and only treatment approved for previously treated advanced NSCLC patients with high c-Met protein overexpression who often face poor prognosis and have limited treatment options – Lung cancer remains the leading cause of cancer-related deaths throughout the worl d1 NORTH CHICAGO, Ill. , May 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that EMRELIS™ (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy. |
prnewswire.com |
2025-05-14 17:09:00 |
Czytaj oryginał (ang.) |
| AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know |
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2025-05-14 14:05:55 |
Czytaj oryginał (ang.) |
| Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck. |
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next. |
barrons.com |
2025-05-14 13:55:00 |
Czytaj oryginał (ang.) |
| AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas |
- Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies across neuroscience, immunology and oncology NORTH CHICAGO, Ill. and SAN DIEGO , May 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology. |
prnewswire.com |
2025-05-14 12:55:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc.(ABBV) of a Class Action Lawsuit and an Upcoming Deadline |
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. |
globenewswire.com |
2025-05-13 16:47:00 |
Czytaj oryginał (ang.) |
| Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared |
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices. |
zacks.com |
2025-05-13 12:40:53 |
Czytaj oryginał (ang.) |
| Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV |
NEW YORK , May 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. |
prnewswire.com |
2025-05-13 09:45:00 |
Czytaj oryginał (ang.) |
| Techbio Pioneer Etcembly Signs Deal With DJS Antibodies, Part of AbbVie, to Accelerate Antibody Discovery Pipeline |
OXFORD, England--(BUSINESS WIRE)-- #biotech--Etcembly has signed a collaboration agreement with DJS Antibodies, a part of AbbVie, to accelerate the discovery of novel antibody therapeutics. |
businesswire.com |
2025-05-12 23:01:00 |
Czytaj oryginał (ang.) |
| Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV |
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). |
globenewswire.com |
2025-05-12 17:18:00 |
Czytaj oryginał (ang.) |
| Drugmakers are spared worst-case drug pricing scenario for now |
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan. |
wsj.com |
2025-05-12 17:14:00 |
Czytaj oryginał (ang.) |
| Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever |
Imagine being able to buy a machine that would work day after day and year after year to make you money. Now imagine being able to buy several such machines. |
fool.com |
2025-02-27 07:47:00 |
Czytaj oryginał (ang.) |
| 2025 Dividend Kings - Off To A Strong Start |
The Dividend Kings are outperforming the S&P 500 in 2025, up 4% YTD versus 1.39% for SPY. Ten Dividend Kings have already achieved double-digit returns, led by National Fuel Gas (+22.08%) and Abbott Laboratories (+20.71%). 2025 Dividend growth is looking promising, with ABM Industries and Walmart leading with 17.78% and 15.69% increases, respectively. |
seekingalpha.com |
2025-02-26 21:07:01 |
Czytaj oryginał (ang.) |
| AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It |
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-02-26 12:05:32 |
Czytaj oryginał (ang.) |
| AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference |
NORTH CHICAGO, Ill. , Feb. 26, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025. |
prnewswire.com |
2025-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here |
Despite significant market events, industrial and tech stocks have had similar returns since 2020, indicating a potential long-term rotation favoring value stocks. Higher inflation and interest rates are shifting the risk/reward balance towards value stocks, making them more attractive compared to growth stocks. The AI revolution and liquidity improvements temporarily boosted growth stocks, but these tailwinds may not sustain long-term outperformance. |
seekingalpha.com |
2025-02-24 09:30:00 |
Czytaj oryginał (ang.) |
| Why AbbVie Remains A Strong Buy For Long-Term Investors |
Why AbbVie Remains A Strong Buy For Long-Term Investors |
seekingalpha.com |
2025-02-23 13:52:22 |
Czytaj oryginał (ang.) |
| 4 Seniors & Aging Demographics Stocks to Watch Right Now |
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare. |
zacks.com |
2025-02-21 14:10:31 |
Czytaj oryginał (ang.) |
| How Dividend Investing Helps Parents Fund College Education Fees |
More than half of parents in the United States emphasize paying for their child's college fees as a main concern. Start a UGMA custodial account early, and use the Dividend Growth Investing strategy to pay for college education and plan for retirement. By starting early and staying disciplined with the Dividend Growth Investing strategy, you can achieve Financial Freedom by your 40s. |
seekingalpha.com |
2025-02-20 12:18:03 |
Czytaj oryginał (ang.) |
| 2 Magnificent Dividend Growth Stocks to Load Up On Right Now |
Dividend stocks have been the backbone of market returns for over a century, contributing roughly two-thirds of total returns since 1900, according to a report by the Hartford Funds. Companies that consistently raise their dividends have been particularly strong performers, thanks to their ability to generate steady revenue growth and strong free cash flows across different market cycles. |
fool.com |
2025-02-20 07:30:00 |
Czytaj oryginał (ang.) |
| AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant |
Since my last analyses on JNJ and ABBV, both have released Q4 earnings. Overall, JNJ showed more pronounced unevenness in its Q4 results, while ABBV's growth story is pretty clear-cut. The goal of this article is to analyze their updates through Graham's framework for picking defensive stocks. |
seekingalpha.com |
2025-02-19 14:26:10 |
Czytaj oryginał (ang.) |
| My Dividend Stock Portfolio: New January Dividend Record - 100 Holdings With 14 Buys |
January saw solid investment activity with $1,500 in net capital added, primarily into Business Development Companies like Owl Rock Capital, Goldman Sachs BDC, and Blackstone Secured Lending Fund. Dividend income hit a record $814 in January, up 21% Y/Y, driven by ongoing investments in high-yield BDCs, aiming for $11,000 annual net dividends. Focus on maintaining steady BDC dividends and achieving a monthly increase of $100 in dividend income. |
seekingalpha.com |
2025-02-19 10:10:00 |
Czytaj oryginał (ang.) |
| Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital |
ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Announces Completion of Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials. |
businesswire.com |
2025-02-19 10:00:00 |
Czytaj oryginał (ang.) |
| AbbVie Appears Ready To Move Higher |
AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment charge from Emraclidine's failure, AbbVie's immunology portfolio, led by Skyrizi and Rinvoq, shows robust growth. AbbVie's diversified portfolio, including drugs from the 2019 Allergan acquisition, continues to mitigate revenue declines from Humira's patent expiration. |
seekingalpha.com |
2025-02-19 00:55:53 |
Czytaj oryginał (ang.) |
| Is AbbVie Stock a Buy Now? |
AbbVie (ABBV -0.30%) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in adjusted earnings per share (EPS), with both metrics exceeding initial guidance. |
fool.com |
2025-02-15 06:55:00 |
Czytaj oryginał (ang.) |
| The Big 3: ABBV, EA, CEG |
Today's Big 3 focuses on companies that couldn't be more different, but @ProsperTradingAcademy's Mike Shorr points to one thing they have in common: choppy price action. He talks about the trends he's watching in AbbVie (ABBV), Electronic Arts (EA), and Constellation Energy (CEG). |
youtube.com |
2025-02-14 13:58:54 |
Czytaj oryginał (ang.) |
| AbbVie: An Undervalued Dividend Aristocrat |
AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets like immunology, neuroscience, and aesthetics, ensuring resilience and a wide moat. AbbVie consistently increases dividends, supported by solid financial health, robust cash reserves, and moderate leverage, reinforcing its attractiveness to investors. |
seekingalpha.com |
2025-02-14 13:00:25 |
Czytaj oryginał (ang.) |
| AbbVie Just Paid Investors: Here's How Much They Received |
AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb. |
247wallst.com |
2025-02-14 10:45:11 |
Czytaj oryginał (ang.) |
| AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors |
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025 NORTH CHICAGO, Ill. , Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. |
prnewswire.com |
2025-02-14 09:40:00 |
Czytaj oryginał (ang.) |
| All-In: The 23-Stock Six-Figure Dividend Portfolio I'm Betting My Future On |
Thank you to the Seeking Alpha community for your support! Reaching 40,000 followers is a dream come true. Your feedback fuels my work. I've invested 91% of my net worth in 23 high-conviction dividend stocks. Focused on wide-moat businesses, I prioritize quality and long-term growth over yield. My portfolio has outperformed the S&P 500, and I'm confident in its future. I expect a rotation to value stocks, and I'll keep sharing insights to grow together. |
seekingalpha.com |
2025-02-14 09:30:00 |
Czytaj oryginał (ang.) |
| AbbVie Declares Quarterly Dividend |
NORTH CHICAGO, Ill. , Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share. |
prnewswire.com |
2025-02-13 13:57:00 |
Czytaj oryginał (ang.) |
| 3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade |
If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constant concern for most families. |
fool.com |
2025-01-04 07:19:00 |
Czytaj oryginał (ang.) |
| AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call |
NORTH CHICAGO, Ill. , Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens. |
prnewswire.com |
2025-01-03 10:00:00 |
Czytaj oryginał (ang.) |
| Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields |
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. |
benzinga.com |
2025-01-03 09:39:42 |
Czytaj oryginał (ang.) |
| The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer |
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog. |
zacks.com |
2025-01-03 05:46:16 |
Czytaj oryginał (ang.) |
| 5 Large Drug Stocks to Keep An Eye On in the New Year |
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio. |
zacks.com |
2025-01-02 12:02:09 |
Czytaj oryginał (ang.) |
| AbbVie (ABBV) Upgraded to Buy: What Does It Mean for the Stock? |
AbbVie (ABBV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-12-31 15:05:24 |
Czytaj oryginał (ang.) |
| Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet |
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. |
zacks.com |
2024-12-31 12:40:48 |
Czytaj oryginał (ang.) |
| AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It |
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2024-12-31 12:16:21 |
Czytaj oryginał (ang.) |
| Highest Quality Dividend Kings For 2025 |
Only 11 Dividend Kings outperformed the S&P 500 during the last decade based on Total Return. 5 Dividend Kings earn the rank of "High Quality" based on my custom quantitative model. Using a variation of a truncated custom quality score could have generated a total return nearly double that of the S&P 500 during the last 9 years. |
seekingalpha.com |
2024-12-30 09:30:00 |
Czytaj oryginał (ang.) |
| The Smartest Dividend Stocks to Buy With $1,000 Right Now |
If you're looking for attractive dividend-paying stocks, that's a smart move. If you're not, perhaps reconsider -- because: |
fool.com |
2024-12-26 07:35:00 |
Czytaj oryginał (ang.) |
| AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing |
In the latest trading session, AbbVie (ABBV) closed at $180, marking a +0.9% move from the previous day. |
zacks.com |
2024-12-24 20:51:36 |
Czytaj oryginał (ang.) |
| Into 2025: Top 8 Stocks I Own And Why (Part II) |
2024 is going out with a bang as mystery drones, Federal Reserve hawkishness, and quantum stocks dominate headlines. It's time to look towards 2025 after another banner year for stocks. Here are four stocks in timely, tremendous industries to keep on your radar. |
seekingalpha.com |
2024-12-24 09:00:00 |
Czytaj oryginał (ang.) |
| Is AbbVie Stock a Buy? |
With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (ABBV 2.37%) is a powerhouse big pharma that has a lot of upside to offer to investors. |
fool.com |
2024-12-23 10:30:00 |
Czytaj oryginał (ang.) |
| 2 Excellent Dividend Stocks to Buy on the Dip |
AbbVie (ABBV 2.37%) and Amgen (AMGN 0.84%) have a lot in common. They are both leading drugmakers and have strong dividend track records. |
fool.com |
2024-12-23 06:32:00 |
Czytaj oryginał (ang.) |
| 2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off |
Stock market investors have plenty of reasons to celebrate as 2024 comes to a close. The S&P 500 index set multiple new record highs during the year, delivering a spectacular 25% return year to date amid a resilient economy and strong corporate earnings. |
fool.com |
2024-12-22 08:50:00 |
Czytaj oryginał (ang.) |
| If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy |
The methodology uses earnings yield, dividend yield, and 5-year dividend CAGR to score and rank 55 stocks across all 11 sectors. Stocks with no dividends are excluded, ensuring a focus on dividend growth, momentum, and value. The top stocks by sector are evaluated and then backtested in an equal weight format. |
seekingalpha.com |
2024-12-21 11:30:00 |
Czytaj oryginał (ang.) |
| 3 Fantastic Stocks That Could Enjoy a Santa Claus Rally |
Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too? |
fool.com |
2024-12-21 08:48:00 |
Czytaj oryginał (ang.) |
| Retirement-Ready Income: 5 Dividend Gems I'd Buy If I Were 65 |
Dividend investing can provide reliable income and peace of mind in retirement. I share five standout picks perfect for a retirement-ready portfolio. These stocks offer strong yields, consistent growth, and robust fundamentals, making them ideal for retirees seeking steady cash flow and stability. Whether you're planning for retirement or already there, these dividend gems combine reliability and long-term potential to help secure your financial future. |
seekingalpha.com |
2024-12-19 09:30:00 |
Czytaj oryginał (ang.) |
| 2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond |
What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase. |
fool.com |
2024-12-19 08:00:00 |
Czytaj oryginał (ang.) |
| Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know |
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2024-12-18 12:06:11 |
Czytaj oryginał (ang.) |